1. Home
  2. EDSA vs ASNS Comparison

EDSA vs ASNS Comparison

Compare EDSA & ASNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • ASNS
  • Stock Information
  • Founded
  • EDSA 2015
  • ASNS 1998
  • Country
  • EDSA Canada
  • ASNS United States
  • Employees
  • EDSA N/A
  • ASNS N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • ASNS Telecommunications Equipment
  • Sector
  • EDSA Health Care
  • ASNS Telecommunications
  • Exchange
  • EDSA Nasdaq
  • ASNS Nasdaq
  • Market Cap
  • EDSA 6.2M
  • ASNS 6.2M
  • IPO Year
  • EDSA N/A
  • ASNS 2022
  • Fundamental
  • Price
  • EDSA $2.03
  • ASNS $0.72
  • Analyst Decision
  • EDSA Strong Buy
  • ASNS Strong Buy
  • Analyst Count
  • EDSA 1
  • ASNS 1
  • Target Price
  • EDSA $21.00
  • ASNS $5.00
  • AVG Volume (30 Days)
  • EDSA 14.5K
  • ASNS 81.3K
  • Earning Date
  • EDSA 05-14-2025
  • ASNS 05-13-2025
  • Dividend Yield
  • EDSA N/A
  • ASNS N/A
  • EPS Growth
  • EDSA N/A
  • ASNS N/A
  • EPS
  • EDSA N/A
  • ASNS N/A
  • Revenue
  • EDSA N/A
  • ASNS $7,755,000.00
  • Revenue This Year
  • EDSA N/A
  • ASNS $31.44
  • Revenue Next Year
  • EDSA N/A
  • ASNS $54.00
  • P/E Ratio
  • EDSA N/A
  • ASNS N/A
  • Revenue Growth
  • EDSA N/A
  • ASNS 72.95
  • 52 Week Low
  • EDSA $1.55
  • ASNS $0.36
  • 52 Week High
  • EDSA $5.59
  • ASNS $4.60
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 36.85
  • ASNS 46.08
  • Support Level
  • EDSA $1.99
  • ASNS $0.70
  • Resistance Level
  • EDSA $2.14
  • ASNS $0.81
  • Average True Range (ATR)
  • EDSA 0.11
  • ASNS 0.06
  • MACD
  • EDSA -0.03
  • ASNS 0.00
  • Stochastic Oscillator
  • EDSA 21.28
  • ASNS 30.23

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About ASNS Actelis Networks Inc.

Actelis Networks Inc is a networking solutions company with a mission to enable communication for Internet of Things, or IoT, projects, deployed over wide areas such as cities, campuses, airports, military bases, roads, and rail. Its networking solutions use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines to create a cost-effective, secure, and quick-to-deploy network. Its solutions also offer end-to-end network security to protect critical IoT data, utilizing a powerful combination of coding and encryption technologies, applied as required on both new and existing infrastructure within the hybrid-fiber-copper network. The company operates as one operating segment: developing and marketing access broadband equipment for copper and fiber networks.

Share on Social Networks: